Literature DB >> 10683053

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.

T J Marrie1, C Y Lau, S L Wheeler, C J Wong, M K Vandervoort, B G Feagan.   

Abstract

CONTEXT: Large variations exist among hospitals in the use of treatment resources for community-acquired pneumonia (CAP). Lack of a common approach to the diagnosis and treatment of CAP has been cited as an explanation for these variations.
OBJECTIVE: To determine if use of a critical pathway improves the efficiency of treatment for CAP without compromising the well-being of patients.
DESIGN: Multicenter controlled clinical trial with cluster randomization and up to 6 weeks of follow-up.
SETTING: Nineteen teaching and community hospitals in Canada. PATIENTS: A total of 1743 patients with CAP presenting to the emergency department at 1 of the participating institutions between January 1 and July 31, 1998. INTERVENTION: Hospitals were assigned to continue conventional management (n = 10) or implement the critical pathway (n = 9), which consisted of a clinical prediction rule to guide the admission decision, levofloxacin therapy, and practice guidelines. MAIN OUTCOME MEASURES: Effectiveness of the critical pathway, as measured by health-related quality of life on the Short-Form 36 Physical Component Summary (SF-36 PCS) scale at 6 weeks; and resource utilization, as measured by the number of bed days per patient managed (BDPM).
RESULTS: Quality of life and the occurrence of complications, readmission, and mortality were not different for the 2 strategies; the 1-sided 95% confidence limit of the between-group difference in the SF-36 PCS change score was 2.4 points, which was within a predefined 3-point boundary for equivalence. Pathway use was associated with a 1.7-day reduction in BDPM (4.4 vs 6.1 days; P = .04) and an 18% decrease in the admission of low-risk patients (31% vs 49%; P = .01). Although inpatients at critical pathway hospitals had more severe disease, they required 1.7 fewer days of intravenous therapy (4.6 vs 6.3 days; P = .01) and were more likely to receive treatment with a single class of antibiotic (64% vs 27%; P<.001).
CONCLUSION: In this study, implementation of a critical pathway reduced the use of institutional resources without causing adverse effects on the well-being of patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683053     DOI: 10.1001/jama.283.6.749

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  135 in total

1.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL Study.

Authors:  D Farquhar
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

3.  Utilization review: can it be improved?

Authors:  J V Tu
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

4.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

5.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 6.  Practice guidelines and measurement: state-of-the-science.

Authors:  Patricia C Dykes
Journal:  Nurs Outlook       Date:  2003 Mar-Apr       Impact factor: 3.250

7.  Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department.

Authors:  S G Campbell; T J Marrie; R Anstey; S Ackroyd-Stolarz; G Dickinson
Journal:  Emerg Med J       Date:  2003-11       Impact factor: 2.740

8.  Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.

Authors:  V Erard; O Lamy; P-Y Bochud; J Bille; A Cometta; T Calandra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-15       Impact factor: 3.267

9.  Development and validation of a short questionnaire in community acquired pneumonia.

Authors:  R El Moussaoui; B C Opmeer; P M M Bossuyt; P Speelman; C A J M de Borgie; J M Prins
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

10.  CDS in a Learning Health Care System: Identifying Physicians' Reasons for Rejection of Best-Practice Recommendations in Pneumonia through Computerized Clinical Decision Support.

Authors:  Barbara E Jones; Dave S Collingridge; Caroline G Vines; Herman Post; John Holmen; Todd L Allen; Peter Haug; Charlene R Weir; Nathan C Dean
Journal:  Appl Clin Inform       Date:  2019-01-02       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.